Gynecologic Cancers

Latest News

The phase 3 ROSELLA trial results assessing relacorliant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.
Relacorilant/Chemo Show Survival Benefit in Platinum-Resistant Ovarian Cancer

April 2nd 2025

The phase 3 ROSELLA trial results assessing relacorliant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Certain subpopulations experienced significantly poorer outcomes in 2020, highlighting concerns regarding access to care.
Vulvar Cancer Survival Discrepancies Seen in Year 1 of COVID-19 Pandemic

March 19th 2025

Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.
Uterine Cancer Survival Rates Have Improved Despite Higher Mortality Risks

March 18th 2025

Despite all groups completing chemoradiation within 56 days, delays contributed to a nonsignificant difference in length between Black vs White patients.
Increased Wait Times Observed for Black/Hispanic Patients With Cervical Cancer

March 18th 2025

The adverse effect profile of abemaciclib plus hormonal therapy was comparable with prior reports of CDK4/6 inhibitors.
Abemaciclib Plus Hormonal Therapy Shows Promising Efficacy in LGSOC/EEC

March 17th 2025

Video Series
Video Interviews
Podcasts
Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.
Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.
Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.
The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.
Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.
Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
Experts from UCLA Health discuss key data presented at The Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer and how they may apply to clinical practice.

More News